Previous 10 | Next 10 |
Endologix ® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has completed enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascul...
Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced its financial results for the first quarter ended March 31, 2020. The Company’s financial results are preliminary and subject to any adj...
Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2020 after the market close on Monday, May 11, 2020. The Company’s management will host a c...
Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Tim A. Benner to succeed John Zehren as the Company’s Chief Commercial Officer, effec...
Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the first quarter ended March 31, 2020 is expected to be approximately $28.5 million. Total cash...
Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Jane E. Kiernan to its board of directors, effective March 12, 2020. Ms. Kiernan has also be...
The FDA approves Endologix's ( ELGX -34.9% ) Alto Abdominal Stent Graft System that, it says, improves short-term outcomes compared to the Ovation iX on the basis of design and manufacturing changes. More news on: Endologix, Inc., Healthcare stocks news, Stocks on the move, Read mo...
Endologix ® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has received approval from the United States Food and Drug Administration (FDA) for the Alto™...
These Top Penny Stocks Have Pushed Higher This Month The coronavirus scare didn’t make a massive dent in the capital markets over the past few weeks. But the dam finally broke on Monday as the real situation seemed to become clearer. On Monday, it emerged that the coronavirus had spread...
Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today that it has entered into an exchange agreement with three holders of the Company’s 3.25% Senior Convertible...
News, Short Squeeze, Breakout and More Instantly...
Shares of Enthusiast Gaming (TSX:EGLX) (NASDAQ:ELGX) soared up to 37% on Tuesday, as the company announced its first-quarter earnings. Enthusiast saw revenue climb 57% year over year to $47.2 million Gross profit jumped 127% to $13.5 million Subscriptions also climbed ...
Commences voluntary Chapter 11 process with access to $30.8 million in DIP financing Files consensual plan of reorganization that would reduce approximately $180 million in debt and provide an approximately $30 million in additional exit financing Confirms launch of Alto thi...
MENLO PARK, Calif. , June 25, 2020 /PRNewswire/ -- Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced two key hires: Sam Park , joining as Chief Operat...